Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease.
acute
emergency department
estimated glomerular filtration rate
kidney disease
soluble urokinase plasminogen activator receptor
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
17
12
2021
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Hospitalized patients are at an increased risk of developing kidney disease after discharge, often despite the absence of any clinical indicators during hospitalization. Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic chronic inflammation that can be measured from routine blood samples. We determined whether elevated suPAR during hospitalization is associated with a decline in estimated glomerular filtration rate (eGFR) after discharge. This was a retrospective longitudinal cohort study of patients without detectable kidney disease presenting to the emergency department on two separate occasions during a 3-year period. The association between suPAR and a decline in eGFR was assessed by linear mixed models for repeated measures adjusting for age, sex, C-reactive protein, sodium, diabetes, hypertension and cardiovascular disease. In total, 5124 patients (median age 65.9 years, 51.0% female) were included. The median suPAR was 2.9 ng/mL, the median time to readmission was 144 days and the expected rate of eGFR decline over this period was 5.1 mL/min/1.73 m A higher suPAR level was associated with accelerated eGFR decline among patients presenting to the emergency department, suggesting that routine suPAR measurements may have utility for the early detection of kidney disease.
Sections du résumé
Background
UNASSIGNED
Hospitalized patients are at an increased risk of developing kidney disease after discharge, often despite the absence of any clinical indicators during hospitalization. Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic chronic inflammation that can be measured from routine blood samples. We determined whether elevated suPAR during hospitalization is associated with a decline in estimated glomerular filtration rate (eGFR) after discharge.
Methods
UNASSIGNED
This was a retrospective longitudinal cohort study of patients without detectable kidney disease presenting to the emergency department on two separate occasions during a 3-year period. The association between suPAR and a decline in eGFR was assessed by linear mixed models for repeated measures adjusting for age, sex, C-reactive protein, sodium, diabetes, hypertension and cardiovascular disease.
Results
UNASSIGNED
In total, 5124 patients (median age 65.9 years, 51.0% female) were included. The median suPAR was 2.9 ng/mL, the median time to readmission was 144 days and the expected rate of eGFR decline over this period was 5.1 mL/min/1.73 m
Conclusions
UNASSIGNED
A higher suPAR level was associated with accelerated eGFR decline among patients presenting to the emergency department, suggesting that routine suPAR measurements may have utility for the early detection of kidney disease.
Identifiants
pubmed: 35892012
doi: 10.1093/ckj/sfac048
pii: sfac048
pmc: PMC9308102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1534-1541Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Am J Kidney Dis. 2003 Oct;42(4):677-84
pubmed: 14520617
J Intern Med. 2010 Sep;268(3):296-308
pubmed: 20561148
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):231-241
pubmed: 29295829
J Am Soc Nephrol. 2017 Oct;28(10):2838-2844
pubmed: 28790143
Diabetes Care. 2019 Jun;42(6):1112-1119
pubmed: 30885954
Am J Kidney Dis. 2008 Oct;52(4):661-71
pubmed: 18805347
Eur J Ageing. 2017 Feb 4;14(3):283-293
pubmed: 28936138
PLoS One. 2015 Jun 10;10(6):e0129036
pubmed: 26061083
N Engl J Med. 2015 Nov 12;373(20):1916-25
pubmed: 26539835
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Clin Med. 2020 Jan 27;9(2):
pubmed: 32012721
Emerg Med J. 2016 Nov;33(11):769-775
pubmed: 27590986
Brain Behav Immun. 2021 Nov;98:263-264
pubmed: 34418502
Clin J Am Soc Nephrol. 2009 Sep;4(9):1432-40
pubmed: 19713288
Front Immunol. 2021 Dec 02;12:780641
pubmed: 34925360
Clin Med (Lond). 2010 Dec;10(6):540-3
pubmed: 21413473
Clin J Am Soc Nephrol. 2021 Sep;16(9):1345-1354
pubmed: 34497110
N Engl J Med. 2020 Jan 30;382(5):416-426
pubmed: 31995687
Kidney Int. 1997 Jun;51(6):1908-19
pubmed: 9186882
Ann Emerg Med. 2013 Jun;61(6):638-43
pubmed: 23415741
Am J Kidney Dis. 2022 Feb;79(2):217-230.e1
pubmed: 34298143
J Am Geriatr Soc. 1985 Apr;33(4):278-85
pubmed: 3989190
QJM. 2015 Oct;108(10):781-7
pubmed: 25636343
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Front Cell Dev Biol. 2020 Jun 12;8:339
pubmed: 32596235
Br J Clin Pharmacol. 2022 Feb;88(4):1679-1690
pubmed: 34242432
Eur J Clin Pharmacol. 2014 Mar;70(3):361-7
pubmed: 24362489
Clin J Am Soc Nephrol. 2021 Jul;16(7):1117-1119
pubmed: 33692116
Crit Care. 2020 Apr 30;24(1):187
pubmed: 32354367
Kidney Int. 2011 Jul;80(1):93-104
pubmed: 21289597
Pharmaceuticals (Basel). 2021 Aug 25;14(9):
pubmed: 34577543
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
Am J Kidney Dis. 2004 Jan;43(1):112-9
pubmed: 14712434
Nat Med. 2017 Aug;23(8):945-953
pubmed: 28650456
Clin J Am Soc Nephrol. 2021 Apr 7;16(4):543-551
pubmed: 33707181
Eur J Clin Invest. 2016 Apr;46(4):305-11
pubmed: 26799247
N Engl J Med. 2011 Dec 22;365(25):2366-76
pubmed: 22077236